PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
0.07
Current Ratio > 1.5x CRVO's 0.00. David Dodd would confirm if this surplus liquidity is put to good use.
0.07
Quick Ratio > 1.5x CRVO's 0.00. David Dodd would verify if the company can handle unexpected shortfalls much better.
0.07
Cash ratio of 0.07 while CRVO has zero cash ratio. Bruce Berkowitz would examine if our cash management provides competitive advantages.
-4.36
Both companies show negative interest coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
No Data
No Data available this quarter, please select a different quarter.